[CANF] Can-Fite Biopharma Ltd

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 30.92 M

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 2.42 Change: -0.01 (-0.41%)
Ext. hours: Change: 0 (0%)

chart CANF

Refresh chart

Strongest Trends Summary For CANF

CANF is in the long-term down -72% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Can-Fite BioPharma, Ltd., a clinical-stage biotechnology company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding13.74 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow-4.27 ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit Operating Profit Total Assets Total Current Assets
Total Current Liabilities Total Debt Total Liabilities Total Revenue
Technical Data
High 52 week2.53 Low 52 week1 Last close1.2 Last change0%
RSI46.51 Average true range0.08 Beta0.52 Volume40.22 K
Simple moving average 20 days0.42% Simple moving average 50 days-3.29% Simple moving average 200 days-5.41%
Performance Data
Performance Week6.19% Performance Month-5.51% Performance Quart-5.51% Performance Half2.56%
Performance Year-47.6% Performance Year-to-date-4.76% Volatility daily3.21% Volatility weekly7.18%
Volatility monthly14.72% Volatility yearly50.99% Relative Volume163.54% Average Volume178.63 K
New High New Low

News

2019-02-27 07:00:00 | Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo

2019-02-25 07:00:00 | Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication

2019-02-04 09:30:00 | Watch These 4 Healthcare Stocks Set The Pace On Monday 2/4/19

2019-02-04 07:00:00 | Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug

2019-01-30 09:35:00 | 4 Healthcare Stocks Raising The Bar On Wednesday 1/30/19

2019-01-30 07:00:00 | Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

2019-01-24 07:30:00 | Can-Fite BioPharma CEO Letter to Shareholders

2019-01-18 08:00:00 | Can-Fite BioPharma Announces Registered Direct Offering

2019-01-08 08:00:00 | Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent

2019-01-03 08:02:00 | Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference

2018-12-10 07:00:00 | Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC

2018-11-30 07:00:00 | Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update

2018-11-20 07:00:00 | Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert

2018-10-31 07:00:00 | Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19

2018-10-25 07:00:00 | Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference

2018-10-18 07:00:00 | Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018

2018-09-12 07:00:00 | Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases AASLD

2018-09-04 07:00:00 | Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year

2018-08-31 07:00:00 | Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update

2018-08-29 07:00:00 | Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018

2018-08-21 07:00:00 | Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis

2018-08-07 09:14:00 | Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China

2018-08-06 05:54:00 | Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical

2018-08-06 05:19:34 | BRIEF-China Medical System Holdings Says It Signed License, Collaboration & Distribution Agreement

2018-07-17 08:56:01 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-17 07:00:00 | Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug

2018-07-02 09:10:15 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-02 07:00:00 | Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer

2018-06-19 07:00:00 | Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial

2018-06-13 08:55:58 | Benzinga Pro's 5 Stocks To Watch Today

2018-06-11 09:32:07 | Benzinga Pro's 5 Stocks To Watch Today

2018-06-11 07:00:00 | Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson

2018-06-01 07:00:00 | Can-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update

2018-04-25 07:00:00 | Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research'

2018-04-13 07:30:00 | Wired News – CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018

2018-04-09 07:00:00 | Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver EASL

2018-03-28 07:00:00 | Can-Fite to Present at the MicroCap Conference

2018-03-23 07:00:00 | Can-Fite Reports 2017 Financial Results & Provides Clinical Update

2018-03-14 07:00:00 | Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference

2018-03-09 09:00:00 | Can-Fite BioPharma Announces $5 Million Registered Direct Offering

2018-03-06 07:00:00 | Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH Conference

2018-03-05 07:00:00 | Can-Fite to Present at the Inaugural LD Micro Virtual Conference

2018-02-28 09:25:00 | Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson

2018-02-22 08:00:00 | Can Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile

2018-02-12 07:00:00 | Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson

2018-01-31 07:00:00 | Can-Fite to Present at BIO CEO & Investor Conference

2018-01-25 07:00:00 | Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries

2018-01-11 07:00:00 | Can-Fite 12 Months' Activities & Milestones for 2018

2018-01-08 07:40:00 | Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings

2018-01-03 07:00:00 | Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH